Saxenda, Victoza (liraglutide) is a protein pharmaceutical. Liraglutide was first approved as Saxenda on 2009-06-30. It has been approved in Europe to treat obesity, overweight, and type 2 diabetes mellitus. The pharmaceutical is active against glucagon-like peptide 1 receptor. Victoza's patents are valid until 2037-01-09 (FDA).
|Trade Name||Saxenda, Victoza|
|Indication||obesity, overweight, type 2 diabetes mellitus|
|Drug Class||Peptides: GLP peptide analogs|